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used as both a proﬁle and single score measure. LiSat-11 is a
generic validated checklist for self-perceived satisfaction with
life. A Finnish, age-matched male population cohort was used
for comparison. RESULTS: A total of 194 patients provided data
for analysis at baseline and outcome at 3 months. The changes
observed (baseline to endpoint) were as follows: average usage
of ED tablets per four weeks increased from 4.7 to 9.7, inter-
course attempts from 6.4 to 10.6, and the success rate of inter-
courses from 79% to 92%. At baseline, the 15D score was higher
for the study patients than for the comparator population (0.924
vs. 0.902). Nevertheless, signiﬁcant improvement (baseline to
endpoint) was reported on the 15D dimensions of mobility,
depression, distress (all p < 0.01), and sexual activity (p < 0.001);
and life in general (p < 0.05), leisure (p < 0.01), sexual life, family
life, and partnership relation (all p < 0.001) domains of LiSat-
11. CONCLUSIONS: When patients switched from other oral
ED medication to tadalaﬁl, improvement was seen in 3 of 15
dimensions of 15D and in 5 out of 11 domains of LiSat-11,
including the closeness items: sexual life, partnership relation,
and family life.
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OBJECTIVE: To estimate the health state utility of differing
severities of gastro-enteritis associated with rotavirus infection in
children under ﬁve. METHODS: Health state descriptions were
developed based on the major symptoms of gastro-enteritis infec-
tion. Health states for children who could be treated at home and
those requiring hospitalisation were presented to GPs (N = 25),
and for hospitalised cases, health states for children with two
levels of dehydration were presented to paediatricians (N = 25).
Both GPs and paediatricians were asked to score these health
states using the EQ-5D questionnaire for children in two age
bands (< 18 months, 1.5–5 years). Scores were modiﬁed to take
into account the limited capacity for mobility and self-care among
children in this age range. Utility estimates were calculated from
these scores using standard methodology. RESULTS: From GP
scores subjects requiring or not hospitalisation have a mean utility
value (95% CI) of 0.425 (95 CI: 0.330; 0.520) and 0.781 (95 CI:
0.678; 0.884) in children <18 months, and 0.200 (95 CI: 0.049;
0.352) and 0.688 (95 CI: 0.553; 0.824) in children 1.5 yrs–5 yrs
respectively. From paediatrician scores, mean utility values for
hospitalised cases with 3–8% and ≥9% dehydration were 0.595
(95 CI: 0.528; 0.662) and 0.256 (95 CI: 0.157; 0.354) in chil-
dren <18 months, and 0.634 (95 CI: 0.549; 0.718) and 0.077 (95
CI: −0.057; 0.210) in children 1.5 yrs–5 yrs respectively. In each
case, conﬁdence intervals between severe and less severe health
states did not overlap. CONCLUSION: Gastroenteritis associ-
ated with rotavirus has a signiﬁcant impact on the health related
quality of life in children under ﬁve. This study provides useful
estimates of health state utilities for economic evaluation of inter-
ventions to prevent rotavirus infection.
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Johnson FR, Hauber B, Ozdemir S
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OBJECTIVE: Demonstrate using conjoint analysis to obtain gen-
eralized, nonlinear, time-tradeoff estimates of quality-adjusted
life-years (QALYs) for clinically relevant durations and severities
of acute, non-fatal conditions such as vasomotor symptoms.
METHODS: A self-administered, web-enabled, graded-pairs
conjoint-analysis survey elicited women’s preferences for the
treatment of vasomotor symptoms. The included treatment
attributes are frequency and severity of vasomotor symptoms
(daytime hot ﬂashes and nighttime sweats) and duration of these
symptoms. Participants also considered vasomotor-symptom,
treatment-related side effects. Observed tradeoffs between
symptom duration and symptom relief were used to calculate
generalized conjoint time equivalents for speciﬁed health states
without ﬁrst calculating utilities anchored at 0 and 1. RESULTS:
A total of 523 women with a mean age of 52 years completed
the survey. For these women, improvement from severe (severe
>6 hot ﬂushes a day and >3 sweats a night) to moderate (mod-
erate 3–6 hot ﬂushes a day and 1–3 sweats a night) vasomotor
symptoms over a 7-year treatment period is equivalent to 3.7
years of normal health, while improvement from moderate to
mild (mild 1–2 hot ﬂushes a day and no night sweats) symptoms
is equivalent to 4.4 years of normal health. QALY beneﬁts of
symptom relief are larger for younger women (<= 2) than for
older women (>52). For example, an improvement from moder-
ate to mild is equivalent to 3.3 years of normal health for
younger women, where it is to 6.8 years of normal health for
older women. CONCLUSIONS: Conjoint analysis is a feasible
method for estimating QALYs directly for acute health states.
This approach avoids ad hoc approaches such as the chaining
method. Its advantages over standard-gamble and time-tradeoff
methods include avoiding clinically irrelevant tradeoffs involv-
ing death or life expectancy, avoiding restrictive assumptions
such as linear time preferences, and eliciting preferences in the
realistic context of both efﬁcacy and side-effect risks.
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Erectile dysfunction (ED) is deﬁned as the persistent or recurring
incapacity to achieve or maintain sufﬁcient rigidity of the penis
to be able to have satisfactory sexual intercourse. OBJECTIVE:
To determine the clinical response to treatment (patient satis-
faction, onset of action and reproducibility of the effect) in
patients with ED, with or without other concomitant diseases.
METHODS: A retrospective, epidemiological study was con-
ducted in which we collected demographic data, medical and
sexual history, concomitant medication, diagnostic and thera-
peutic procedures applied to ED and the clinical response to the
prescribed treatment in male patients over 18 years of age who
had visited their doctor in the 3 months prior to the start of the
study. RESULTS: data was collected from 5281 patients. The
most prevalent associated disorders were cardiovascular
(28.6%), endocrine (23.7%) and genitourinary (15.4%). A total
of 77.1% of the patients with concomitant disorders indicated
they were satisﬁed with the erection obtained (sufﬁcient for inter-
course) (90.9% of the patients without other associated disor-
ders; p < 0.0001). A totalof he patients with concomitant
diseases referred they were satisﬁed with the onset of action of
the treatment (91.1% without other associated disorders; p <
0.0001). 75.8% of the patients with concomitant diseases were
conﬁdent to obtain and maintain a sufﬁcient erection at each new
attempt (90.0% without other associated disorders; p < 0.0001).
Clinical response was better in patients with cardiovascular or
endocrine conditions vs. genitourinary disorders (p < 0.03; p <
0.04). The mean prescribed dose was 15.9 mg (SD 5.2) of var-
denaﬁl, 18.6 mg (SD 6.9) of tadalaﬁl and 60.6 mg (SD 23.7) of
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sildenaﬁl. CONCLUSIONS: Patients with ED without other rel-
evant concomitant diseases showed better clinical response to
treatment than those suffering from associated conditions.
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OBJECTIVES: Prior to use in an international study by NV
Organon, the original 48-item menstrual Distress Questionnaire
(MDQ), underwent linguistic validation in 26 languages. The
original scale was developed in US English to assess the impact
of common symptoms and feelings associated with the menstrual
cycle. A rigorous methodology was required to ensure concep-
tual equivalence and cultural relevance across different lan-
guages. METHODS: The translation process was conducted by
a specialist in each target country using the following standard-
ized methodology: 1) two forward translations by professional
translators who were native speakers of the target language and
ﬂuent in English; 2) comparison and reconciliation of the trans-
lations by the specialist in the target country and the translators;
3) back-translation by a native English speaker; 4) comparison
of the original and back-translated versions; 5) review by a clin-
ician; 6) comprehension test on 5 women; and 7) review for
international comparability. RESULTS: The translation process
revealed two major challenges. First, the formulation of some
original items required the addition of a paraphrase or explana-
tion in some languages. Second, the comprehension tests revealed
that in countries where women are less used to completing ques-
tionnaires, the instructions asking the respondent to rate the
same symptom/feeling for different times during a menstrual
cycle were not always understood immediately. This required
alternative wording in some translations. CONCLUSION: The
26 language versions of the MDQ were established according to
a rigorous standardized translation methodology. The process
aims to ensure conceptual equivalence across language versions
to facilitate international comparison and pooling of data. The
linguistic validation process illustrates the value of the integra-
tion of international feedback on concepts and wording during
the translation of questionnaires.
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Erectile dysfunction (ED) is deﬁned as the persistent or recurring
incapacity to achieve or maintain sufﬁcient rigidity of the penis
to be able to have satisfactory sexual intercourse. OBJECTIVES:
To determine the clinical evaluation of the treatments prescribed
in Spain for ED in terms of efﬁcacy, patient satisfaction, onset
of action, tolerability and reproducibility of the effect.
METHODS: A retrospective epidemiological study was con-
ducted in which we collected demographic data, medical and
sexual history, concomitant medication, diagnostic and thera-
peutic procedures applied to ED and clinical response to the pre-
scribed treatment, in male patients over 18 years of age who had
visited a doctor in the 3 months prior to the start of the study.
RESULTS: Data was collected from 5281 patients. 86.8% of
those taking vardenaﬁl obtained an erection that was sufﬁcient
for satisfactory intercourse vs. 59.1% with tadalaﬁl and 45.2%
with sildenaﬁl (p < 0.0001). The time required to obtain the erec-
tion was considered satisfactory in 89.7% of the patients taking
vardenaﬁl vs. 65.2% with tadalaﬁl and 44.8% with sildenaﬁl (p
< 0.0001). The tolerability of the prescribed treatment was sat-
isfactory in 94.3% of the patients who took vardenaﬁl vs. 77.8%
with tadalaﬁl and 74.0% with sildenaﬁl (p < 0.0001). A total of
85.7% of the patients with ED who took vardenaﬁl referred they
were conﬁdent that they could obtain and maintain a sufﬁcient
erection in each new attempt vs. 57.1% with tadalaﬁl and 44.6%
with sildenaﬁl (p < 0.0001). The mean prescribed dose of var-
denaﬁl was 15.9 mg (SD 5.2), 18.6 mg (SD 6.9) for tadalaﬁl and
60.6 mg (SD 23.7) for sildenaﬁl.CONCLUSIONS: Oral treat-
ments for erectile dysfunction provide a good clinical response,
observing a statistically higher response with vardenaﬁl at a
lower dose.
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OBJECTIVE: To explore the feasibility of producing preferences
in the Italian context. METHODS: We carried out a pilot expe-
rience to assess the preferences of Italian patients (pts) suffering
from benign prostatic hyperplasia, using different techniques. Pts
expressed their opinions on different scenarios (with/without
drugs, TURP). Outcomes to be evaluated were: symptoms relief,
risk of urinary retention, adverse events (AEs) etc. Pts were asked
to: 1) rank the scenarios according to their preferences; 2) rate
(0 to 100) any scenario: and 3) express their Willingness to Pay
for each scenario. RESULTS: On a sample of 51 pts, the differ-
ent methods showed similar results except for WTP, whose ratio-
nale was difﬁcult to understand by pts. Among preference
factors, pts ranked reducing the prostate volume and the risk of
surgery at the top of the list; while reducing the risk of urinary
retention and avoiding AEs were at the end. Data processing
showed an inverse relation between preferences of minimizing
AEs and efﬁcacy. CONCLUSIONS: We found a lot of difﬁcul-
ties in measuring health preferences. The acceptance to take part
into the study was poor. It is likely that the poor acceptance
reﬂects the lack of interest by urologists and pts. Furthermore,
the number of published papers on preferences by Italian authors
is very scarce. In our opinion, likely explanations of this is that
a) in Italy the National Health Service is free/almost free for
everybody, and this leads to a difﬁcult evaluation (in economic
terms) of a health care intervention; b) scenarios to be evaluated
are theoretical, not experienced by pts; c) in a solidarity health
service (as the Italian one) the health decision-making is based
on political and social basis, and not only on economic analysis;
and d) usually the health decisions are based on a quantitative,
and not qualitative, approach.
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OBJECTIVES: To assess the inﬂuence of vardenaﬁl on treatment
satisfaction in men with erectile dysfunction (ED) and their
female partners. METHODS: This was a retrospective pooled
analysis of three multicentre, double-blind, ﬂexible-dose,
placebo-controlled clinical studies of vardenaﬁl vs. placebo for
12 weeks, in men with ED for at least 6 months duration, and
